Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nu Planet Pharmaceutical Radioisotopes
AddedFeb 16, 2024
UpdatedJun 18, 2026
Nu Planet Pharmaceutical Radioisotopes

Nu Planet Pharmaceutical Radioisotopes

Nu Planet innovates in nuclear physics, producing cost-effective, scalable rare isotopes for pharma, energy, space & defense sectors.

HQ
Scottsdale, AZ, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Nu Planet Pharmaceutical Radioisotopes, founded by Dr. Steve Howe, focuses on innovating within the nuclear physics sector to produce cost-effective and scalable rare isotopes. Their core mission is to revolutionize the supply chain for isotopes used in pharmaceuticals, energy, space, and defense industries. By leveraging a multi-isotope production platform, Nu Planet aims to significantly reduce costs and create a sustainable economic advantage in a multi-billion-dollar market.

Dr. Steve Howe, with affiliations to Los Alamos and Idaho Labs, leads the company. Nu Planet has attracted notable investors due to its groundbreaking approach and potential market impact. Key achievements include the development of a scalable production process that outperforms current cost benchmarks. The company's innovations promise to enhance the availability and affordability of critical isotopes, thereby driving advancements across multiple high-tech industries.

Similar Companies

Nucleus RadioPharma logo

Nucleus RadioPharma

nucleusrad.com

NorthStar Medical Radioisotopes logo

NorthStar Medical Radioisotopes

Atomic Alchemy logo

Atomic Alchemy

Arizona Isotope Science Research logo

Arizona Isotope Science Research

azisotopes.org

Alpha Source logo

Alpha Source

alphasource.com

Northwest Medical Isotopes logo

Northwest Medical Isotopes

Niowave logo

Niowave

niowaveinc.com

Coqui Radio Pharmaceuticals logo

Coqui Radio Pharmaceuticals

Nuclearn logo

Nuclearn

Phoenix Nuclear Labs logo

Phoenix Nuclear Labs

Radionetics Oncology logo

Radionetics Oncology

radionetics.com

NuView Life Sciences logo

NuView Life Sciences

Radiant logo

Radiant

radiantnuclear.com

Nano Nuclear Energy logo

Nano Nuclear Energy

Vivos logo

Vivos

radiogel.com

Nu Planet Pharmaceutical Radioisotopes - Quick Facts

Who are Nu Planet Pharmaceutical Radioisotopes' competitors?

Companies similar to Nu Planet Pharmaceutical Radioisotopes include Nucleus RadioPharma, NorthStar Medical Radioisotopes, Atomic Alchemy and Arizona Isotope Science Research.

When was Nu Planet Pharmaceutical Radioisotopes founded?

Nu Planet Pharmaceutical Radioisotopes was founded in 2021.

Where is Nu Planet Pharmaceutical Radioisotopes' headquarters located?

Nu Planet Pharmaceutical Radioisotopes' headquarters is located in Scottsdale, AZ, US.

When was Nu Planet Pharmaceutical Radioisotopes' last funding round?

Nu Planet Pharmaceutical Radioisotopes' most recent funding round was for $1.2M (USD) in January 2022.

How much has Nu Planet Pharmaceutical Radioisotopes raised to-date?

As of Jan 1, 2022, Nu Planet Pharmaceutical Radioisotopes has raised a total of $1.2M (USD).

How many employees does Nu Planet Pharmaceutical Radioisotopes have?

Nu Planet Pharmaceutical Radioisotopes has 5 employees as of Feb 4, 2024.

Nu Planet Pharmaceutical Radioisotopes - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Nuclear Physics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Radioisotopes
Tags
  • Biotech